MS-OVA given in a tumor-bearing mouse was capable of activating and expanding OVA-CD8+ T cells from 0.1% (data not shown) up to 10% of all circulating CD8+ T cells in the blood sampled on days 15 and 30 after tumor challenge (Figure 1B). The gene discussed is CD8A; the disease is neoplasm.